切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2025, Vol. 19 ›› Issue (02) : 146 -151. doi: 10.3877/cma.j.issn.1674-3253.2025.02.004

专家论坛

体液外泌体在前列腺癌诊断中的应用前景
杨健1, 杨璐1,()   
  1. 1. 610041 成都,四川大学华西医院泌尿外科
  • 收稿日期:2025-01-20 出版日期:2025-04-01
  • 通信作者: 杨璐
  • 基金资助:
    国家自然科学基金项目(82372831)

The application prospects of exosomes in the diagnosis of prostate cancer

Jian Yang1, Lu Yang1,()   

  1. 1. Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China
  • Received:2025-01-20 Published:2025-04-01
  • Corresponding author: Lu Yang
引用本文:

杨健, 杨璐. 体液外泌体在前列腺癌诊断中的应用前景[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(02): 146-151.

Jian Yang, Lu Yang. The application prospects of exosomes in the diagnosis of prostate cancer[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 146-151.

近年来受环境污染、饮食变化等因素影响,前列腺癌(PCa)发病率逐渐升高,影响男性健康及生命安全,而早期准确的诊治是延长患者生存时间的关键。既往采用前列腺特异性抗原(PSA)对PCa 进行诊断,但其易受年龄及炎症影响出现误诊,继而需进行穿刺活检,而穿刺活检存在一定创伤,故急需新的生物标志物来提高对PCa 的临床诊断,并指导治疗决策。外泌体属于细胞外囊泡的一个亚类,可作为细胞间信息传递的载体,已有研究表明外泌体中含有对PCa 进展至关重要的多种蛋白质及RNA,在PCa 诊断方面具有潜力。本文综述了外泌体生物学特性,及其在PCa 发展中的作用,并阐述其在PCa 诊断、治疗方面的应用前景。

In recent years,due to environmental pollution,dietary changes and other factors,the incidence rate of prostate cancer (PCa) has gradually increased,affecting male's health and life expectancy.Early and accurate diagnosis and treatment are keys to prolonging the survival time of patients.Previously,prostate-specific antigen (PSA) was used for the diagnosis of prostate cancer (PCa),but it was prone to misdiagnosis due to factors such as age and inflammation,necessitating biopsy.However,biopsy is invasive,so new biomarkers are urgently needed to improve the clinical diagnosis of PCa and guide treatment decisions.Exosomes belong to a subclass of extracellular vesicles and can serve as carriers for intercellular information transmission.Previous studies have shown that exosomes contain various proteins and RNAs that are crucial for the progression of PCa,and have potential in PCa diagnosis.This article reviews the biological characteristics of exosomes,their role in the development of PCa,and elaborates on their potential applications in the diagnosis and treatment of PCa.

图1 外泌体的产生过程示意图 注:右侧外泌体结构部分CD63,CD9,CD81,TSG101,ARF6,Alix均为蛋白标志物
[1]
Williams IS,McVey A,Perera S,et al.Modern paradigms for prostate cancer detection and management[J].Med J Aust,2022,217(8): 424-433.DOI: 10.5694/mja2.51722.
[2]
Achard V,Putora PM,Omlin A,et al.Metastatic prostate cancer:treatment options[J].Oncology,2022,100(1): 48-59.DOI:10.1159/000519861.
[3]
Bochner E,Gold S,Raj GV.Emerging hormonal agents for the treatment of prostate cancer[J].Expert Opin Emerg Drugs,2022,27(3): 301-309.DOI: 10.1080/14728214.2022.2121390.
[4]
Salciccia S,Frisenda M,Bevilacqua G,et al.Exosome analysis in prostate cancer: how they can improve biomarkers' performance[J].Curr Issues Mol Biol,2023,45(7): 6085-6096.DOI: 10.3390/cimb45070384.
[5]
邹宇健,陈林.环状RNA 在前列腺癌中的研究进展[J].中华男科学杂志,2022,28(7): 649-655.DOI:10.13263/j.cnki.nja.2022.07.013.Zou YJ,Chen L.Research progress of cyclic RNA in prostate cancer[J].Natl J Androl,2022,28(7): 649-655.DOI: 10.13263/j.cnki.nja.2022.07.013.
[6]
Yu W,Hurley J,Roberts D,et al.Exosome-based liquid biopsies in cancer: opportunities and challenges[J].Ann Oncol,2021,32(4):466-477.DOI: 10.1016/j.annonc.2021.01.074.
[7]
Albino D,Falcione M,Uboldi V,et al.Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer[J].Commun Biol,2021,4(1): 119.DOI: 10.1038/s42003-020-01642-5.
[8]
Johnstone RM,Adam M,Hammond JR,et al.Vesicle formation during reticulocyte maturation.Association of plasma membrane activities with released vesicles (exosomes)[J].J Biol Chem,1987,262(19): 9412-9420.
[9]
Grimaldi AM,Salvatore M,Cavaliere C.Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: a systematic review of the literature[J].Prostate Cancer Prostatic Dis,2023,26(2): 228-239.DOI: 10.1038/s41391-022-00521-w.
[10]
崔凌煦,红华,梁丹艳,等.经直肠超声造影联合血清外泌体对早期前列腺癌的诊断价值[J].中华实用诊断与治疗杂志,2022,36(11): 1145-1148.DOI: 10.13507/j.issn.1674-3474.2022.11.015.Cui LX,Hong H,Liang DY,et al.Value of transrectal contrastenhanced ultrasound combined with serum exosomes to the diagnosis of early prostate cancer[J].Chin J Pract Diagn Ther,2022,36(11):1145-1148.DOI: 10.13507/j.issn.1674-3474.2022.11.015.
[11]
Li S,Zhao Y,Chen W,et al.Exosomal ephrinA2 derived from serum as a potential biomarker for prostate cancer[J].J Cancer,2018,9(15):2659-2665.DOI: 10.7150/jca.25201.
[12]
Sung BH,Ketova T,Hoshino D,et al.Directional cell movement through tissues is controlled by exosome secretion[J].Nat Commun,2015,6: 7164.DOI: 10.1038/ncomms8164.
[13]
Larson J,Ozen MO,Kohli M,et al.Systematic analysis of tissuederived and biofluid extracellular vesicle miRNAs associated with prostate cancer[J].Adv Biol,2023,7(7): e2200327.DOI: 10.1002/adbi.202200327.
[14]
Urabe F,Yamamoto Y,Kimura T.miRNAs in prostate cancer:Intercellular and extracellular communications[J].Int J Urol,2022,29(12): 1429-1438.DOI: 10.1111/iju.15043.
[15]
田野,阿不都米吉提·阿不都克力木,王鹏,等.肿瘤相关巨噬细胞极化状态对前列腺癌干细胞自我更新能力和血管生成拟态的影响[J].吉林大学学报(医学版),2022,48(2): 374-382.DOI:10.13481/j.1671-587X.20220214.Tian Y,AbuduKelimu A,Wang P,et al.Effects of tumor-associated macrophage polarization status on self-renewal capacity and angiogenic mimicry of prostate cancer stem cells[J].J Jilin Univ (Med Ed),2022,48(2): 374-382.DOI: 10.13481/j.1671-587X.20220214.
[16]
王雅轩.血管生成及干性特征相关标志物在前列腺癌中的研究进展[J].中华男科学杂志,2023,29(10): 944-948.DOI: 10.13263/j.cnki.nja.2023.10.014.Wang YX.Progress of angiogenesis and stemness characterizationrelated markers in prostate cancer[J].Natl J Androl,2023,29(10):944-948.DOI: 10.13263/j.cnki.nja.2023.10.014.
[17]
梁博,刘军,姜明东,等.人脐间充质干细胞外泌体通过miR-126-3p 抑制前列腺癌生长的相关研究[J].中国性科学,2022,31(2): 16-20.DOI: 10.3969/j.issn.1672-1993.2022.02.005.Liang B,Liu J,Jiang MD,et al.Correlative study of human umbilical cord mesenchymal stem cell exosomes inhibiting prostate cancer growth via miR-126-3p[J].Chin J Hum Sex,2022,31(2): 16-20.DOI: 10.3969/j.issn.1672-1993.2022.02.005.
[18]
Wu M,Wang G,Hu W,et al.Emerging roles and therapeutic value of exosomes in cancer metastasis[J].Mol Cancer,2019,18(1): 53.DOI:10.1186/s12943-019-0964-8.
[19]
Bao L,You B,Shi S,et al.Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10[J].Oncogene,2018,37(21): 2873-2889.DOI: 10.1038/s41388-018-0183-6.
[20]
张清元,刘敏,陆江婷,等.ABCC4 基因表达对前列腺癌免疫微环境的影响[J].广西医科大学学报,2023,40(2):245-253.DOI:10.16190/j.cnki.45-1211/r.2023.02.010.Zhang QY,Liu M,Lu JT,et al.Effect of ABCC4 gene expression on the immune microenvironment of prostate cancer[J].J Guangxi Med Univ,2023,40(2):245-253.DOI:10.16190/j.cnki.45-1211/r.2023.02.010.
[21]
邵波,万水,田申,等.基于细胞焦亡基因前列腺癌预后模型的构建及肿瘤微环境分析[J].癌症进展,2024,22(2): 176-182.DOI:10.11877/j.issn.1672-1535.2024.22.02.15.Shao B,Wan S,Tian S,et al.Construction of a prognostic model of prostate cancer based on pyroptosis gene and analysis of tumor microenvironment[J].Oncol Prog,2024,22(2): 176-182.DOI:10.11877/j.issn.1672-1535.2024.22.02.15.
[22]
Chowdhury R,Webber JP,Gurney M,et al.Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and proinvasive myofibroblasts[J].Oncotarget,2015,6(2): 715-731.DOI:10.18632/oncotarget.2711.
[23]
Hsu YL,Hung JY,Chang WA,et al.Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1[J].Oncogene,2017,36(34): 4929-4942.DOI: 10.1038/onc.2017.105.
[24]
叶芸.外泌体介导miR-141 调控前列腺癌骨转移微环境的分子机制[D].西安,中国人民解放军空军军医大学,2018.Ye Y.Molecular mechanism of exosomes mediating mir-141 regulating microenvironment of prostate cancer bone metastasis[D].Xian,Air Forco Medical University,2018.
[25]
郑乃盛,汪婷婷,袁向亮,等.肿瘤相关巨噬细胞来源外泌体激活IFN 通路促进胃癌细胞免疫逃逸[J].现代免疫学,2021,41(1):24-31.DOI: 1001-2478(2021)01-0024-08.Zheng NS,Wang TT,Yuan XL,et al.Tumor-associated macrophagesderived exosomes promote immune escape of gastric cancer cells via IFN pathway[J].Curr Immunol,2021,41(1): 24-31.DOI:1001-2478(2021)01-0024-08.
[26]
Lundholm M,Schröder M,Nagaeva O,et al.Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion[J].PLoS One,2014,9(9): e108925.DOI: 10.1371/journal.pone.0108925.
[27]
Salimu J,Webber J,Gurney M,et al.Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes[J].J Extracell Vesicles,2017,6(1): 1368823.DOI:10.1080/20013078.2017.1368823.
[28]
Li W,Dong Y,Wang KJ,et al.Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer[J].Neoplasma,2020,67(6): 1314-1318.DOI: 10.4149/neo_2020_191130N1234.
[29]
Duca RB,Massillo C,Dalton GN,et al.miR-19b-3p and miR-101-3p as potential biomarkers for prostate cancer diagnosis and prognosis[J].Am J Cancer Res,2021,11(6): 2802-2820.
[30]
Zhou C,Chen Y,He X,et al.Functional implication of exosomal miR-217 and miR-23b-3p in the progression of prostate cancer[J].Onco Targets Ther,2020,13: 11595-11606.DOI: 10.2147/OTT.S272869.
[31]
Wang J,Ni J,Beretov J,et al.Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer[J].Crit Rev Oncol Hematol,2020,145:102860.DOI: 10.1016/j.critrevonc.2019.102860.
[32]
Foj L,Ferrer F,Serra M,et al.Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis[J].Prostate,2017,77(6): 573-583.DOI: 10.1002/pros.23295.
[33]
Holdmann J,Markert L,Klinger C,et al.microRNAs from urinary exosomes as alternative biomarkers in the differentiation of benign and malignant prostate diseases[J].J Circ Biomark,2022,11: 5-13.DOI: 10.33393/jcb.2022.2317.
[34]
李腊秀,马越云,李卓,等.尿液exosomal miR-375 在前列腺癌诊断中的价值初探[J].中华检验医学杂志,2017,40(4): 273-277.DOI: 10.3760/cma.j.issn.1009-9158.2017.04.012.Li (L/X)X,Ma YY,Li Z,et al.Exosome-encapsulated miR-375 in urine as a non-invasive biomarker for prostate cancer diagnosis[J].Chin J Lab Med,2017,40(4): 273-277.DOI: 10.3760/cma.j.issn.1009-9158.2017.04.012.
[35]
Shin S,Park YH,Jung SH,et al.Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J].NPJ Genom Med,2021,6(1): 45.DOI: 10.1038/s41525-021-00212-w.
[36]
Kim MY,Shin H,Moon HW,et al.Urinary exosomal microRNA profiling in intermediate-risk prostate cancer[J].Sci Rep,2021,11(1):7355.DOI: 10.1038/s41598-021-86785-z.
[37]
赵晓东,陈颖琦,刘喆,等.外泌体作为新型诊断标志物在前列腺癌中的研究进展[J].中华男科学杂志,2022,28(12): 1123-1128.DOI: 10.13263/j.cnki.nja.2022.12.011.Zhao XD,Chen YQ,Liu Z,et al.Exosomes in the diagnosis of prostate cancer: Advances in studies[J].Natl J Androl,2022,28(12):1123-1128.DOI: 10.13263/j.cnki.nja.2022.12.011.
[38]
Barceló M,Castells M,Bassas L,et al.Semen miRNAs contained in exosomes as non-invasive biomarkers for prostate cancer diagnosis[J].Sci Rep,2019,9(1): 13772.DOI: 10.1038/s41598-019-50172-6.
[39]
Ghosh S,Garg S,Ghosh S.Cell-derived exosome therapy: a novel approach to treat post-traumatic brain injury mediated neural injury[J].ACS Chem Neurosci,2020,11(14): 2045-2047.DOI:10.1021/acschemneuro.0c00368.
[40]
Saari H,Lázaro-Ibáñez E,Viitala T,et al.Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells[J].J Control Release,2015,220(Pt B): 727-737.DOI: 10.1016/j.jconrel.2015.09.031.
[41]
吕立国,吴巧玲,黄娟,等.含蜂毒肽的前列腺癌外泌体制备及体外评价[J].中国药理学通报,2023,39(2): 392-399.DOI:10.12360/CPB202203104.Lv LG,Wu QL,Huang J,et al.Preparation and in vitro evaluation of exosomes containing bee venom peptide for prostate cancer[J].Chin J Pharmacol,2023,39(2): 392-399.DOI:10.12360/CPB202203104.
[42]
Kyuno D,Zhao K,Bauer N,et al.Therapeutic targeting cancerinitiating cell markers by exosome miRNA: efficacy and functional consequences exemplified for claudin7 and EpCAM[J].Transl Oncol,2019,12(2): 191-199.DOI: 10.1016/j.tranon.2018.08.021.
[43]
杜秋伶,钟惟德.前列腺癌的药物治疗研究进展及展望[J].中华实验外科杂志,2023,40(12): 2429-2436.DOI: 10.3760/cma.j.cn421213-20230416-01120.Du QL,Zhong WD.Research progress and prospects of drug treatment for prostate cancer[J].Chin J Exp Surg,2023,40(12):2429-2436.DOI: 10.3760/cma.j.cn421213-20230416-01120.
[1] 黄晓芳, 刘澍雨, 黄子荣, 胡艳, 梁家敏, 朱伟民. 软骨细胞来源外泌体对于软骨损伤修复的研究进展[J/OL]. 中华关节外科杂志(电子版), 2024, 18(06): 751-758.
[2] 张晓波, 巴特, 黄瑞娟, 王宏宇. 间充质干细胞外泌体改善急性肺损伤机制的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(01): 81-85.
[3] 曾繁润, 林永勇, 王君. 间充质干细胞外泌体促进创面血管新生机制的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(01): 86-89.
[4] 宋勤琴, 李双汝, 李林, 杜鹃, 刘继松. 间充质干细胞源性外泌体在改善病理性瘢痕中作用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 550-553.
[5] 潘麒文, 何立儒. 前列腺癌放射治疗前沿进展荟萃[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(02): 279-279.
[6] 李永红, 王骏, 肖恒军. 2025-NCCN前列腺癌诊治指南更新解读[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(02): 129-133.
[7] 邱皓炜, 徐臻, 肖泽秀, 夏燕, 查高峰, 庞俊. 前列腺癌mRNA 疫苗研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(02): 134-139.
[8] 刘咏博, 郭佳. 外泌体在前列腺癌细胞免疫逃逸中的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(02): 140-145.
[9] 罗添龙, 贺情情, 黄海. 泌尿功能障碍慢性病的长期综合管理和持久康复实践[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 21-26.
[10] 祝炜安, 林华慧, 吴建杰, 黄炯煅, 吴婷婷, 赖文杰. RDM1通过CDK4促进前列腺癌细胞进展的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 618-625.
[11] 王功炜, 李书豪, 魏松, 吕博然, 胡成. 溶瘤病毒M1对不同前列腺癌细胞杀伤效果的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 626-632.
[12] 施一辉, 张平新, 朱勇, 杨德林. 机器人辅助前列腺根治术后切缘阳性的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 633-637.
[13] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[14] 陈博滔, 胡宽, 毛先海. 胆囊癌肿瘤微环境与系统治疗[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 203-208.
[15] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
阅读次数
全文


摘要